Crossmark

Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders

Published Online: 2020-07-11

Published Print: 2020-09

Authors

Karpen, Saul J. https://orcid.org/0000-0002-3379-7592
Kelly, Deirdre

Mack, Cara

Stein, Philip
Funding

Funding for this research was provided by:

Albireo AB
License Information

Text and Data Mining valid from 2020-07-11

Version of Record valid from 2020-07-11
More Information

Article History

Received: 20 April 2020

Accepted: 22 June 2020

First Online: 11 July 2020

Compliance with ethical standards

:

: Saul J. Karpen is a consultant for Albireo, Intercept, LogicBio, Mirum, and Spruce Biosciences. Deirdre Kelly is a consultant for Albireo, and her unit receives research funding for clinical trials from Albireo, Intercept, and Mirum. Cara Mack is a consultant for Albireo. Philip Stein is an employee of Albireo Pharma, Inc.

: This article does not contain any studies with human participants or animals performed by any of the authors.

Document is current